To see the other types of publications on this topic, follow the link: HR 1817.
Journal articles on the topic 'HR 1817'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'HR 1817.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Budding, E., B. D. Carter, M. W. Mengel, O. B. Slee, and J. F. Donati. "A Radio and Optical Study of the Active Young F Star HR 1817 (=HD 35850)." Publications of the Astronomical Society of Australia 19, no. 4 (2002): 527–33. http://dx.doi.org/10.1071/as02021.
Full textAbstract:
AbstractThis paper presents the results of a multiwavelength observational study of the active young F-type star HR 1817. The star was monitored at 4.80 and 8.64 GHz over 2 × 12 h allocations with the Australia Telescope Compact Array on 8 and 9 December, 2000. The Anglo-Australian Telescope was used for simultaneous optical spectropolarimetry during a 2 h period on 9 December.The low levels of observed radio emission have characteristics that are similar to those seen in other active stars, and a gyrosynchrotron mechanism is proposed to explain them; this is supported by the relatively low fractions of circular polarisation measured in HR 1817.Comparison of the emissions from 4.80 and 8.64 GHz shows a very strong cross-correlation peak, indicative of a common origin, although the shift of this peak indicates that 8.64 GHz variations tend to precede those at 4.80 GHz by, typically, ˜20 min.The optical spectropolarimetry reveals polarisation signals characteristic of surface magnetic fields, with profile changes indicating a complex dynamo-type magnetic topology is present on the star. This result makes HR 1817 the star with the earliest spectral type on which dynamo magnetic fields have been detected directly up to now.
2
Pavlenko, O., I. Maksymenko, Ie Lapin, and V. Kasianenko. "ANALYSIS OF THE EFFICIENCY OF PERSONNEL WORK AS AN ELEMENT OF THE ENTERPRISE BUSINESS PROCESS." Vìsnik Sumsʹkogo deržavnogo unìversitetu, no. 1 (2019): 77–81. http://dx.doi.org/10.21272/1817-9215.2019.1-10.
Full textAbstract:
Nowadays, the search for the effective tools in a sphere of personnel management are still on, and these issues is crucial especially for the Ukrainian enterprises. The article is aimed to analyze the effectiveness of staff as an element of the business-processes system of an enterprise. Among all the approaches the authors put their attention to evolutional and revolutional approaches to reengineering of the business-processes, and the key role of the personnel in these processes. Particular attention was given to the identification of personnel management essence in terms of business-process management, the pathways of optimizations of the business-processes, .and the main problems of HR-management that can be identified under the audit process. The case methodology was used to reveal the best practices in the improvement of HR-management system. Keywords: personnel, business process, analysis, enterprise, management.
3
Telyshevska, L., and V. Uspalenko. "The trends in the development of the HR management system at the enterprise." Economic Herald of the Donbas, no. 2 (56) (2019): 187–97. http://dx.doi.org/10.12958/1817-3772-2019-2(56)-187-197.
Full text
4
Lukianykhin, V., O. Lukianykhina, and Ya Sorokolit. "FINANCIAL INCLUSION AS A DRIVER PROVIDING FINANCIAL SECURITY IN UKRAINE." Vìsnik Sumsʹkogo deržavnogo unìversitetu, no. 2 (2020): 79–89. http://dx.doi.org/10.21272/1817-9215.2020.2-9.
Full textAbstract:
The article explores and summarizes the approaches of scientists to the definition of "personnel management", forms the author's definition as a set of interrelated methods, principles and forms of organizational mechanism for the formation, reproduction, development and utilization of personnel, creating optimal work conditions and employee motivation. The application of personnel management methods in successful business entities is analyzed on the example of companies included in the rankings of the best employers of Ukraine, in particular, whose production facilities are located in Sumy region - "Mondelis Ukraine" (Trostyanets) and "Farmak" (Shostka). It is concluded that the successful implementation of personnel management strategy (HR-strategy) is possible only with the correct composition of tools of administrative and economic influence, which can be supported (depending on financial capacity, management sentiment, accepted business practices, etc.) by socio-psychological methods. According to Hay-McBerAssociates' approach, six leadership styles have been identified. The author's vision presents their evolution (from the use of mostly administrative to the most modern methods (including coaching). The personnel management system of the «Sumy Road Maintenance Department Branch» has been studied. An assessment of the capabilities of this company to improve the efficiency of the existing personnel management system was made. Proposals for modernization of personnel management policy within the framework of administrative and economic methods in their interconnection and effective interaction are given. The most appropriate style of personnel management at the current stage of development of the organization is "visionary", which contributes to the formation of a successful long-term development strategy and the creation of perspectives for staff. But in today's reality, this style must be abandoned with the prospect of moving to a democratic version, reducing the share of administrative methods and increasing the importance of economic methods as more progressive methods of stimulating labor. In addition, it is determined that to increase the efficiency of personnel management of the Branch it is proposed to use modern HR-software with the use of cloud technologies for application in management activities. The analysis of IT-operators and their products allowed to identify quite interesting proposals (Microsoft, SAP, Terrasoft), but the main limitation to the use of these programs in the activities of the Branch is the high cost of use (up to 50,000 UAH / month). That is why we offer to utilize the software product "PeopleHR" of the company "PeopleFource", which has not yet gained much popularity in the Ukrainian market. This is a fairly full-featured program aimed at medium-sized businesses. It was also decided to focus on the system of additional bonuses for staff depending on the length of service and compliance with labour discipline, as the most effective method of improving the efficiency of employees.
5
Zhulavskiy, A., V. Hordiienko, and N. Malko. "PROFESSIONAL COMPETENCE OF CIVIL SERVANTS AS A FACTOR OF SUCCESS OF PUBLIC MANAGER." Vìsnik Sumsʹkogo deržavnogo unìversitetu, no. 4 (2020): 152–57. http://dx.doi.org/10.21272/1817-9215.2020.4-17.
Full textAbstract:
The article is devoted to the actual issues of professional competence of civil servants in the system of effective public administration. It was found out that official duties of a state body require professional knowledge and certain competencies of a civil servant how to properly apply them. The analysis of the legislative and regulatory framework in the field of civil service shows that a concept as "professional competence of civil servants." Undergoes formation of its foundations and development. The precondition for the formation of competencies for an employee is determined by the position requirements and job responsibilities. The role of the head of the state body, his/her vision and style of management of the institution and staff, his/her fairness and professionalism in the selection of specialists play an important role. The analysis of the procedure of civil servant evaluation, servant’s activities during the last year and the effectiveness of the tasks set by the head of the civil service indicates a constant need to increase the level of professional competence of the employees. Activities of an HR specialist or service, who is responsible for supporting employees in personal, professional and competence growth through elaborating individual plans and training schemes. Approaches to evaluate activities of civil servants and impact of these activities were identified. The current state of implementation of the system of training and re-training, the basic requirements and types of educational services, platforms, including online, were assessed. Basic requirements to professional competence of civil servants necessary for effective work of public authorities were identified. The ways to solve and improve the mechanisms of realization civil service policies, namely improvement of the system of increase of professional competence of civil servants, were suggested. Considering the long-term public administration reform in Ukraine, the government's focus on the gradual provision of public institutions with competent and professional employees who would meet European standards, was identified.
6
Karu, Einar, Mengze Li, Lisa Ernle, Carl A. M. Brenninkmeijer, Jos Lelieveld, and Jonathan Williams. "Atomic emission detector with gas chromatographic separation and cryogenic pre-concentration (CryoTrap–GC–AED) for atmospheric trace gas measurements." Atmospheric Measurement Techniques 14, no. 3 (March 4, 2021): 1817–31. http://dx.doi.org/10.5194/amt-14-1817-2021.
Full textAbstract:
Abstract. A gas detection system has been developed, characterized, and deployed for pressurized gas-phase sample analyses and near-real-time online measurements. It consists of a cryogenic pre-concentrator (CryoTrap), a gas chromatograph (GC), and a new high-resolution atomic emission detector (AED III HR). Here the CryoTrap–GC–AED instrumental setup is presented, and the performance for iodine (1635 ± 135 counts I atom−1 pptv−1), sulfur (409 ± 57 counts S atom−1 pptv−1), carbon (636 ± 69 counts C atom−1 pptv−1), bromine (9.1 ± 1.8 counts Br atom−1 pptv−1), and nitrogen (28 ± 2 counts N atom−1 pptv−1) emission lines is reported and discussed. The limits of detection (LODs) are in the low parts per trillion by volume range (0.5–9.7 pptv), and the signal is linear to at least 4 orders of magnitude, which makes it a suitable method for diverse volatile organic compound (VOC) measurements in the atmosphere, even in remote unpolluted regions. The new system was utilized in a field study in a boreal forest at Hyytiälä, Finland, in late summer 2016, which made monoterpene measurements possible among other VOCs. Furthermore, pressurized global whole-air samples, collected on board the Lufthansa Airbus A340-600 IAGOS–CARIBIC aircraft in the upper troposphere and lower stratosphere region, were measured with the new setup, providing data for many VOCs, including the long-lived organosulfur compound carbonyl sulfide.
7
Pestaña-Fernández, Melani, Manuel Rubio-Rivas, Carles Tolosa-Vilella, Alfredo Guillén-Del-Castillo, Mayka Freire, Jose Antonio Vargas-Hitos, Jose Antonio Todolí-Parra, et al. "Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study." Journal of Rheumatology 47, no. 1 (February 15, 2019): 89–98. http://dx.doi.org/10.3899/jrheum.180595.
Full textAbstract:
Objective.Monotherapy is an option as first-line therapy for pulmonary arterial hypertension (PAH). However, combination therapy is a beneficial alternative. Our objective was to evaluate the efficacy of monotherapy versus combination therapy in patients with systemic sclerosis (SSc)–associated PAH.Methods.All patients with SSc-associated PAH from the Spanish Scleroderma Registry (RESCLE) were reviewed. Patients were split into 3 groups: monotherapy versus sequential combination versus upfront combination therapy. The primary endpoint was death from any cause at 1, 3, and 5 years from PAH diagnosis.Results.Seventy-six patients (4.2%) out of 1817 had SSc-related PAH. Thirty-four patients (45%) were receiving monotherapy [endothelin receptor antagonist (n = 22; 29%) or phosphodiesterase-5 inhibitors (n = 12; 16%)], 25 (33%) sequential combination, and 17 (22%) upfront combination therapy. A lower forced vital capacity/DLCO in the sequential combination group was reported (2.9 ± 1.1 vs 1.8 ± 0.4 vs 2.3 ± 0.8; p = 0.085) and also a higher mean pulmonary arterial pressure in combination groups (37.2 ± 8.7 mmHg vs 40.8 ± 8.8 vs 46 ± 15.9; p = 0.026) at baseline. Treatment regimen (p = 0.017) and functional class (p = 0.007) were found to be independent predictors of mortality. Sequential combination therapy was found to be an independent protective factor (HR 0.11, 95% CI 0.03–0.51; p = 0.004), while upfront combination therapy showed a trend (HR 0.68, 95% CI 0.23–1.97; p = 0.476). Survival from PAH diagnosis among monotherapy, sequential, and upfront combination groups was 78% versus 95.8% versus 94.1% at 1 year, 40.7% versus 81.5% versus 51.8% at 3 years, and 31.6% versus 56.5% versus 34.5% at 5 years (p = 0.007), respectively. Side effects were not significantly different among groups.Conclusion.Combination sequential therapy improved survival in our cohort.
8
Sawyer, M. B., S. Damaraju, E. Pituskin, V. Damaraju, A. G. Scarfe, R. B. Bies, J. Hanson, M. Clemons, M. Kuzma, and J. R. Mackey. "Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 2504. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.2504.
Full textAbstract:
2504 Background: Epirubicin (EPI) is widely used to treat breast cancer. EPI is predominantly metabolized by uridine glucuronosyltransferase (UGT) 2B7 to inactive glucuronides. We previously showed that a UGT enhancer single nucleotide polymorphism (SNP) at position -161 T to C correlated with rates of morphine glucuronidation. Methods: We performed a prospective pharmacogenetic study of effects of this SNP on EPI metabolism in M0 breast cancer patients (PTS) receiving adjuvant or neoadjuvant FEC100 (5-fluorouracil 500 mg/m2, EPI 100 mg/m2 and cyclophosphamide 500 mg/m2) given every 3 wks. PTS with ALT and AST ≤ upper limit of normal (ULN), a total bilirubin ≤ ULN, and normal renal and cardiac function were eligible. EPI levels were drawn at approximately 1 and 24 hrs. Cycle 1 toxicities were assessed using NCIC CTG toxicity criteria. Results: 123 PTS entered this study, mean (range): age 51 (28 - 74), sex 122 F/ 1 M, baseline AST 24 U/L (13–66), ALT 22 U/L (5–90), bilirubin 8 μmol/L (2–26), creatinine 74 μmol/L (50 - 126). PTS were genotyped using Pyrosequencing; 26 PTS were TT homozygotes, 59 were CT heterozygotes, and 33 were CC homozygotes. 5 PTS could not be genotyped. A three compartment population pharmacokinetic model in NONMEM V 1.1 for EPI was used incorporating all PTS. The baseline objective function was 1817, and inclusion of genotype significantly improved the objective function to 1764; CC genotype PTS had decreased EPI clearance 88.9 L/hr compared to CT/TT genotype PTS 129 L/hr, p<0.001. Rates of first cycle grade 3/4 leucopenia were 78% in CC PTS and 48% in CT/TT PTS; consistent with the pharmacokinetic analysis. Conclusions: A SNP in UGT 2B7 is common and appears to predicts EPI clearance and myelosuppresion in non-metastatic breast cancer PTS and may form the basis for a method to individualize EPI treatment. No significant financial relationships to disclose.
9
Kaga, Yasuhiro, Yu Sunakawa, Yutaro Kubota, Teppei Tagawa, Taikan Yamamoto, Toshikazu Ikusue, Yu Uto, et al. "Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX." Journal of Clinical Oncology 34, no. 4_suppl (February 1, 2016): 237. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.237.
Full textAbstract:
237 Background: Results from the phase III PRODIGE 4/ACCORD 11 trial provided one of current standard regimens for advanced pancreatic cancer (PC), consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX), which has superior response rate (RR) and survival benefit even with severe toxicity (Thierry C, et al. N Engl J Med 2011;364:1817-1825). There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in PC. We therefore analyzed retrospectively whether the ETS will predict outcomes in pts with PC treated with FOLFIRINOX therapy. Methods: Advanced PC pts with ECOG PS of 0 or 1, who received FOLFIRINOX as 1st- or 2nd-line treatment between November 2012 and July 2015 in 3 institutes of Showa University were included in this analysis. ETS was defined as a reduction ≥ 20% of target lesions’ diameters measured at 8 weeks from treatment start. We evaluated the association of ETS with progression-free survival (PFS) and overall survival (OS) but also addressed the correlation between outcomes and DpR, which was percentage of maximal tumor shrinkage observed at the nadir diameter compared with baseline. Results: Fifty-nine PC pts with median age of 63 (range 34-76) years and males of 68% were enrolled: 80% of pts had metastatic disease. In the population, RR, median PFS, and OS were 28%, 5.4 months, and 10.7 months, respectively. Among 46 (78%) evaluable pts for the ETS, 12 (26%) pts experienced ETS. The PFS was significantly longer in pts with ETS compared to pts with no ETS (9.0 vs. 4.2 months, HR 0.43, 95%CI 0.17-0.96, log-rank P= 0.045). Moreover, pts with ETS had a better OS although no statistical significance (HR 0.53, log-rank P= 0.25). Median DpR was 11.1% (from -75.7 to 100), and the correlation of DpR with clinical outcome was observed (P= 0.024 for PFS, P= 0.22 for OS). Conclusions: This retrospective analysis suggests that the early response to FOLFIRINOX treatment may predict better outcomes in pts with advanced PC. The ETS may serve as a novel predictor of prolonged survival time in PC pts treated with FOLFIRINOX.
10
Cluzeau, Thomas, Guillaume Robert, Jean-Michel Karsenti, Frederic Luciano, Alexandre Puissant, S. Dominique Raynaud, Lionel Mannone, Jill-Patrice Cassuto, Nicolas Mounier, and Patrick Auberger. "Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines." Blood 116, no. 21 (November 19, 2010): 1817. http://dx.doi.org/10.1182/blood.v116.21.1817.1817.
Full textAbstract:
Abstract Abstract 1817 Azacitidine (AZA) is the first line treatment for IPSS (index prognostic scoring system) high-risk myelodysplastic syndrome (HR-MDS). To date, only Khan et al. (Exp Hematol. 2008) and Hollenbach et al. (PLoS One. 2009) have reported apoptosis as a mechanism of AZA effect on MDS cell lines. Nevertheless, approximately 40% of patients treated with AZA are refractory to this molecule. To investigate the possible mechanisms of AZA resistance in MDS cells, we developped AZA-resistant cell clones (AZA-R) from the well-characterized MDS cell line SKM1. The bulk resistant SKM1 cell line (AZA-R) was obtained following long time exposure of cells to iterative and increasing doses of AZA ranging from 0.1 to 8mM. We first showed that AZA triggered loss of cell metabolism in SKM1 parental cells but not in their AZA-resistant counterpart at a maximally effective dose of 1mM. AZA-mediated loss of cell metabolism accounted mainly for induction of apoptosis as judged by both an increase in caspase 9 and 3 activities triggered by this compound and by a significant protection in the presence of the pan-caspase inhibitor Z-VAD-fmk in SKM1 parental cells. Conversely, no or very few activation of caspases and apoptosis were detected in AZA-R cells strongly suggesting that apoptosis is impaired in AZA-R SKM1 cells. Finally, unlike in SKM1 cells, AZA failed to induce mitochondrial membrane permeabilization in AZA-R SKM1 cells. Importantly, basal autophagy was increased in AZA-R versus AZA-S cells as shown by LC3-I cleavage into LC3-II, p62/SQSTM1 protein expression, cathepsin B activation, mTOR and S6 ribosomal protein dephosphorylation and finally electronic microscopy experiments. In addition, Acadesine, an adenosine derivative and AMPK agonist which targets autophagy was capable to circumvent AZA resistance in both AZA-R SKM1 cells and in medullary cells from five MDS patients resistant to AZA after 6 cycles of Azacitidine. In conclusion, targeting autophagy appears as an attractive therapeutical strategy to circumvent AZA resistance in both established MDS cell lines and cells from MDS patients. Therefore, drugs capable of inducing autophagy or autophagic cell death, such as Acadesine (Robert et al., PLoS One. 2009) which is currently in phase II clinical trials for the treatment of Chronic Lymphoblastic Leukemia could be also beneficial for HR-MDS patients resistant to AZA. Disclosures: Cluzeau: Celgene: Consultancy. Raynaud:Celgene: Consultancy.
11
Lebedev, V. V., O. V. Kozhevnikova, O. S. Logacheva, E. E. Akhmedova, I. K. Filimonova, E. N. Basargina, L. A. Gandaeva, et al. "Comorbidity of sleep disorders in children with cardiomyopathies." Voprosy praktičeskoj pediatrii 15, no. 5 (2020): 24–33. http://dx.doi.org/10.20953/1817-7646-2020-5-24-33.
Full textAbstract:
Objective. To analyze clinical and instrumental characteristics of sleep disorders in children with cardiomyopathies (CMPs). Patients and methods. We performed retrospective analysis of clinical, laboratory, and instrumental parameters in 107 children with CMPs aged 2 to 17 years treated in the National Medical Research Center of Children's Health in 2018–2019. The study sample was formed in accordance with inclusion criteria (confirmed diagnosis of CMP with functional class I or II, NYHA or Ross R.D.) and exclusion criteria (age <2 years, other heart and vascular diseases). We enrolled 26 children with hypertrophic CMP, 63 children with dilated CMP, and 18 children with unclassified CMP. According to the signs of sleep disorders (from sleep questionnaires filled in by parents), we formed 3 groups: patients with no sleep disorders (n = 40), patients with symptoms of insomnia/parasomnia (n = 26), and patients with indirect and/or direct signs of sleep apnea syndrome (SAS). We analyzed patients’ complaints, as well as clinical, instrumental (liver ultrasound, echocardiography, Holter ECG), and laboratory (glucose, cholesterol, alanine aminotransferase, and aspartate aminotransferase in serum) parameters. Results. Sleep disorders were identified in 63% of children: 58% had signs of insomnia/parasomnia and 38% had signs of SAS. In contrast to the questionnaires, medical records had information about sleep disorders only in two cases. Medical records primarily contained complaints of fatigue and reduced tolerance to physical activity (73%), excessive sweating (23%), and shortness of breath (17%). Patients with SAS usually had more complaints (according to their medical records), and their complaints were more diverse, including abnormal blood pressure, cephalgia, palpitations, and syncope. Body mass index (BMI) (p = 0.001) and serum glucose (p = 0.001) were higher in children with SAS than in children with normal sleep. Even after the exclusion of BMI, glucose levels (although being within the reference range) were still significantly higher in the SAS group (p = 0.020). The QTc interval at the maximum heart rate (HR) (p = 0.018) in children with sleep disorders was longer and had a positive correlation with serum glucose level (r = 0.195, p = 0.052). The analysis of echocardiography parameters (excluding the diagnosis factor) showed a smaller diameter of the pulmonary artery (p = 0.058) in children with SAS and correlation between right atrial remodeling and the factor of sleep disorder in children with various forms of CMP (p = 0.040). Conclusion. The analysis of sleep questionnaires revealed sleep disorders in 63% of children with CMP, including insomnia/parasomnia (24%) and/or SAS (38%). The presence of SAS was associated with a substantial number and variety of subjective complaints. The signs of myocardial electrical instability (longer QTc interval at maximum heart rate), association between QTc and serum glucose level, specific features of remodeling of the heart and blood vessels in patients with sleep disorders, and, most importantly, SAS in children indicate the need for early detection and correction of sleep disorders (insomnia, parasomnia) and main causes of SAS, such as chronic diseases of the ENT organs, overweight, and obesity. Treatment of sleep disorders is very important in terms of prevention of complications, treatment and prognosis of cardiomyopathy in children, which will help to increase therapeutic efficacy. Key words: children, cardiomyopathy, comorbidity, sleep disorders, sleep apnea, sleep questionnaires
12
Tsvetkov, Yuriy A. "HR BRAND OF AN INVESTIGATIVE AUTHORITY." Russian investigator 4 (April 15, 2020): 61–64. http://dx.doi.org/10.18572/1812-3783-2020-4-61-64.
Full text
13
Park, Na-yeon. "The Progression and Its Meaning of Designation Ceremonyof Crown Prince in 1812." Humanities Research 62 (August 31, 2021): 609–46. http://dx.doi.org/10.52743/hr.62.20.
Full text
14
Perraky, Vivi. "Grégoire Zalykis. Face à trois grands philologues francais sur la prononciation du grec (1809-1810)." Historical Review/La Revue Historique 6 (January 25, 2010): 53. http://dx.doi.org/10.12681/hr.240.
Full text
15
Zhukova, L. G., I. P. Ganshina, O. O. Gordeeva, and E. V. Lubennikova. "Ribociclib in 1st line HR+ breast cancer treatment." Journal of Modern Oncology 20, no. 2 (June 15, 2018): 38–41. http://dx.doi.org/10.26442/1815-1434_2018.2.38-41.
Full textAbstract:
Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.
16
Yakovaki, Nassia. "The Philiki Etaireia Revisited: In Search of Contexts, National and International." Historical Review/La Revue Historique 11 (December 5, 2014): 171. http://dx.doi.org/10.12681/hr.334.
Full textAbstract:
It is perhaps not an exaggeration to say that studies on the Philiki Etaireia (1814-1821), a field of historical research that has evolved in a rather marginal, if not erratic way, are lately at a standstill; at the same time, however, the Age of Revolution – and, more to the point, the until recently understudied post-Napoleonic decades – is the object of a remarkable renewal of interest among historians internationally. This essay tries to place the life and deeds of the Philiki Etaireia once more on the agenda of social and political history of the period, not only of the Balkans and the Ottoman Empire, but also of post-Napoleonic Europe, by revisiting the case of this (much acclaimed in the Greek national narrative) secret society and bringing forward possible new contexts for better understanding its emergence and development.
17
Tolias, George. "Antiquarianism, Patriotism and Empire: Transfers of the Cartography of The Travels of Anacharsis the Younger in Greece (1788-1811)." Historical Review/La Revue Historique 2 (January 20, 2006): 67. http://dx.doi.org/10.12681/hr.184.
Full textAbstract:
<p>The aim of this paper is to present an instance of cultural transfer within the field of late Enlightenment antiquarian cartography of Greece, examining a series of maps printed in French and Greek, in Paris and Vienna, between 1788 and 1811 and related to Abbé Barthélemy's <em>Travels of Anacharsis the Younger in Greece</em>. The case study analyses the alterations of the content of the work and the changes of its symbolic functions, alterations due first to the transferral of medium (from a textual description to a cartographic representation) and next, to the successive transfers of the work in diverse cultural environments. The transfer process makes it possible to investigate some aspects of the interplay of classical studies, antiquarian erudition and politics as a form of interaction between the French and the Greek intelligentsia of the period.</p>
18
Kirillina, S. A. "ХождениеиеромонахаЛеонтиявЕгипет иПалестинув17631766гг.:Исламиегоносители в«историижизнимладшего Григоровича»." Istoricheskii vestnik, no. 20(2017) part: 20 (August 30, 2019): 190–217. http://dx.doi.org/10.35549/hr.2019.2017.35083.
Full textAbstract:
Leonty (born as Luka Stepanovich Zelensky in 1726, died in 1807), priestmonk from the Monastery of the Exaltation of the Holy Cross in Poltava, undertook the pilgrimage to the Holy Land in 1763 1766. His itinerary included Egypt, the Sinai Peninsula and Palestine. After his trip to Levant he arrived to Istanbul where he became the chaplain of the church attached to the Russian Embassy. Since that time, the Ottoman capital became his home for the rest of his days. He only left Istanbul for Russia twice in 1771 1775 and 1787 1793. In 1767 Leonty was honoured the title of archimandrite. In 1788 the cleric resigned from the pastoral service and in his advanced age painstakingly worked on his multivolume autobiography. The first three volumes of Leontys memoirs are dedicated to the detailed and vivid description of his pilgrimage to the renowned holy places of Egypt and Palestine. Leontys memoirs are a quaint mixture of various facts, inner dialogues and personal observations of the local inhabitants, their occupations and lifestyles he encountered, including established beliefs, manners and customs. The aim of the present article is to survey particular facets of Leontys narrative as a valuable source for scholars dealing with Ottoman history and to examine his ambivalent attitude towards Islam and its followers living in the ArabOttoman world.Иеромонах полтавского Крестовоздвиженского монастыря (the Monastery of the Exaltation of the Holy Cross in Poltava) Леония (в миру Лука Степанович Зеленский) (1726 1807) совершил хождение в Святую землю в 1763 1766 гг. Его маршрут включал посещение мест поклонения в Египте, включая Синай, и Палестине. По завершении паломничества он остался на службе в церкви при российском посольстве в Стамбуле, где прожил до конца жизни. В России ему довелось побывать в России только дважды в 1771 1775 гг. и 1787 1793 гг. В 1767 г. Леоний был возведен в сан архимандрита, а в 1788 г. он оставил место церковного настоятеля и на закате жизни всецело отдался литературному творчеству. Его перу принадлежит тринадцатитомные мемуары, первые три тома которой посвящены описанию его путешествия к святым местам Египта и Палестины. Сочинение Леонтия лишено композиционного единства и представляет собой причудливую смесь разнообразных фактов, бытовых и психологических зарисовок, метких наблюдений и внутренних диалогов, в которых исследователи найдут много важного и полезного. Одним из сюжетов, привлекательных для историковвостоковедов, является тема отношения российского богомольца к исламу и его последователям представителям арабоосманского мира.
19
Niu, Wenquan, Yue Qi, Yuesheng Qian, Pingjin Gao, and Dingliang Zhu. "The relationship between apolipoprotein E ɛ2/ɛ3/ɛ4 polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls." Hypertension Research 32, no. 12 (October 9, 2009): 1060–66. http://dx.doi.org/10.1038/hr.2009.164.
Full text
20
Nord, Deborah Epstein. "Karen A. Weisman. Singing in a Foreign Land: Anglo-Jewish Poetry, 1812–1847." University of Toronto Quarterly 89, no. 3 (February 2021): 582–83. http://dx.doi.org/10.3138/utq.89.3.hr.35.
Full text
21
Pavlovschi, Ecaterina, Valeriana Pantea, Djina Borovic, and Olga Tagadiuc. "Study of ischemia modified albumin (IMA) as a biomarker in hypertensive retinopathy." Medicine and Pharmacy Reports 94, no. 2 (April 29, 2021): 185–90. http://dx.doi.org/10.15386/mpr-1815.
Full textAbstract:
Background. Hypertension (HTN) is one of the leading causes of morbidity and mortality worldwide. A prompt diagnosis and treatment of hypertensive retinopathy (HR), the leading complication of HTN is pivotal for a better visual outcome. Increased blood pressure on its own cannot fully clarify the development of retinal alterations, therefore an additional pathogenetic mechanism, such as oxidative stress, might be inquired.
The aim of the study was to evaluate the changes in the level of ischemia modified albumin (IMA) in the serum and tears of HR patients in order to establish the predictive value of IMA for the HR progression.
Methods. Serum and tear samples for the measurement of IMA were collected from 90 patients detected primarily with HR, who were not taking any antihypertensive or other drug that could influence the results of the study, divided according to the Keith-Wagener classification into GI ‒ 36 patients with HR grade I, GII ‒ 35 with HR grade II and GIII ‒ 19 with HR grade III. Serum and tear IMA levels were assessed using the Co2+ binding method (Gudumac V. et al., 2009) and expressed as median and interquartile range. Kruskal-Wallis and Mann-Whitney nonparametric tests were used to compare the groups and the Spearman correlation coefficient was calculated (SPSS 23.0), with p<0.05 being statistically significant.
Results. The groups showed a statistically significant difference in serum IMA (p=0.006), the values increasing in parallel with the progression of HR. The serum IMA level in GII increased compared to GI (+3%; 239.06 µM/L (IQR 75.58) vs 231.77 µM/L (IQR 104.09), p=1.00), as well as in GIII patients compared to GII (+17%; 277.67 µM/L (IQR 88.72) vs 239.06 µM/L (IQR 75.58), p=0.04). There were no differences in IMA content (p=0.160), between groups in the tears. No correlations were found between serum and tear IMA levels (p=0.134), but serum IMA showed a significant moderate strength, positive correlation with the degree of HR (r=0.307**, p=0.003).
Conclusion. A progressive enhancement in serum IMA level as HR advanced was identified. Thereby, the results suggest the potential relevance of serum IMA as a sensitive and early biomarker useful for grading and optimal treatment of the patients with HR.
22
TAGLIAFERRO, Elaine Pereira da Silva, Vanessa PARDI, Gláucia Maria Bovi AMBROSANO, Marcelo de Castro MENEGHIM, Marco Aurelio Benini PASCHOAL, Rita de Cássia Loiola CORDEIRO, and Antonio Carlos PEREIRA. "Influence of caries risk on the retention of a resin-modified glass ionomer used as occlusal sealant: a clinical trial." Revista de Odontologia da UNESP 46, no. 4 (August 21, 2017): 208–13. http://dx.doi.org/10.1590/1807-2577.18116.
Full textAbstract:
Abstract Introduction Little is known whether caries risk influence occlusal sealants retention. Objective To determine the retention rates (RR) of the resin-modified glass ionomer cement used as occlusal sealant in permanent first molars of 6-8-year old schoolchildren and to analyze the influence of caries risk at baseline on the RR of the sealant, over a 24-month period. Material and method The sealant application was performed in a dental office at the beginning of the study, after children being allocated into high caries risk group (HR) and low caries risk group (LR). The examinations were performed by the same calibrated dentist at 0, 6, 12, 18 and 24 months. Retention rates were estimated, the Kaplan-Meier method was used to estimate the survival probabilities; and the comparison between HR and LR groups was evaluated by Wilcoxon and log-rank test. Result The results showed that 14% of sealed teeth showed total loss (16% for HR and 12% for LR) and 46% showed partial loss during the study (51% for HR and 41% for LR), in relation to the baseline sample. No difference could be demonstrated by the survival analysis between HR and LR groups (p>0.05). Conclusion Caries risk did not influence the retention rates of a resin-modified glass ionomer cement used as occlusal sealant in 6-8-year old schoolchildren.
23
Lu, Huajun, Chaoqun Wang, Lijun Xue, Qi Zhang, Frank Luh, Jianghai Wang, Tiffany G. Lin, Yun Yen, and Xiyong Liu. "Human Mitotic Centromere-Associated Kinesin Is Targeted by MicroRNA 485-5p/181c and Prognosticates Poor Survivability of Breast Cancer." Journal of Oncology 2019 (April 3, 2019): 1–13. http://dx.doi.org/10.1155/2019/2316237.
Full textAbstract:
Purpose. This study aims to evaluate the prognostic value of human Mitotic Centromere-Associated Kinesin (MCAK), a microtubule-dependent molecular motor, in breast cancers. The posttranscriptional regulation of MCAK by microRNAs will also be explored.Methods. The large-scale gene expression datasets of breast cancer (total n=4,677) were obtained from GEO, NKI, and TCGA database. Kaplan-Meier and Cox analyses were used for survival analysis. MicroRNAs targeting MCAK were predicted by bioinformatic analysis and validated by a dual-luciferase reporter assay.Results. The expression of MCAK was significantly associated with aggressive features of breast cancer, including tumor stage, Elston grade, and molecular subtypes, for global gene expression datasets of breast cancer (p<0.05). Overexpression of MCAK was significantly associated with poor outcome in a dose-dependent manner for either ER-positive or ER-negative breast cancer. Evidence from bioinformatic prediction, coexpression assays, and gene set enrichment analyses suggested that miR-485-5p and miR-181c might target MCAK and suppress its expression. A 3’UTR dual-luciferase target reporter assay demonstrated that miR-485-5p and miR-181c mimics specifically inhibited relative Firefly/Renilla luciferase activity by about 50% in corresponding reporter plasmids. Further survival analysis also revealed that miR-485-5p (HR=0.59, 95% CI 0.37-0.92) and miR-181c (HR=0.54, 95% CI 0.34-0.84) played opposite roles of MCAK (HR=2.80, 95% CI 1.77-4.57) and were significantly associated with better outcome in breast cancers.Conclusion. MCAK could serve as a prognostic biomarker for breast cancers. miR-485-5p and miR-181c could specifically target and suppress the MCAK gene expression in breast cancer cells.
24
Furuya, R., S. Akiu, M. Fukuda, and T. Hirobe. "156 The changes in the function of primary melanocytes derived from (HR-1 X HR/De)F1 hairless mice during the development of UVB-induced pigmented spots." Journal of Dermatological Science 10, no. 1 (July 1995): 88. http://dx.doi.org/10.1016/0923-1811(95)93870-7.
Full text
25
Gaken, Joop, Azim M. Mohamedali, Natalie Twine, Nigel Westwood, Barbara Czepulkowski, Saousan Chehade, Lynn S. Quek, Nicholas Lea, and Ghulam J. Mufti. "MicroRNA Expression Profiling of High and Low Risk MDS." Blood 112, no. 11 (November 16, 2008): 3645. http://dx.doi.org/10.1182/blood.v112.11.3645.3645.
Full textAbstract:
Abstract MicroRNA’s (miR) are small noncoding RNA’s of 18–25 nucleotides that have a critical impact on gene regulation affecting cell growth & differentiation. Importantly, miR expression profiles can help distinguish normal cells from cancerous cells. This is particularly relevant to myelodysplastic syndromes both because of their heterogeneity as well as the difficulties associated with the early diagnosis of these disorders. We investigated the miR profiles of CD34+ and total nucleated cells (TNC) from different subtypes of MDS (n=135) and compared these to AML (n=20), normal CD34+ (n=5) and normal TNC’s (n=6). We used the Illumina universal array matrix to interrogate 470 validated miR’s from the Sanger mir-Base database and a further 265 putative miR’s from the literature. Array intensity data was analysed using the Partek Genomics Suite v6.3. Data was normalised using quantile normalisation and unchanging miR’s removed. A 1-way ANOVA was used to identify differentially expressed miR’s and a FDR correction applied to control for Type I errors. Our initial analysis compared TNC (n=6) with CD34 cells (n=5) from normal controls. As expected both groups clustered separately with mir-199a (p<10−9), mir-30a-3p (p<10−7), mir-507 (p<10−7) showing the most significant differences out of a total of 250 differentially expressed miR’s. Our results clearly identified an expression signature for low risk (LR), high risk (HR) and AML using data from both TNC’s and CD34+ cells compared to normal TNC and CD34+ cells. Cluster analysis of miR’s of CD34+ cells from normal controls (n=5) and monosomy 7 (−7) patients (n=6) identified a panel of 18 miR’s that differentiated both groups. Similarly, analysis of CD34+ cells from HR MDS (n=7) and normal CD34+ controls identified a unique panel of 34 miR’s differentiating both groups. Analysis of CD34+ cells from both del(5q) (n=4) and LR MDS cases (n=8) identified a panel of 154 and 23 miR’s respectively that differentiated these from the normal controls. A 4-way intersect analysis of miR expression from CD34+ cells from LR, HR, del(5q) and −7 groups did not identify any common miR’s when compared to normal CD34+ cells. However, a 3-way analysis using LR, HR and −7 groups identified mir-34a as a single common miR. The mir-34 family (a, b, c) are transcriptional targets for p53 and have been shown to be induced by DNA damage and oncogenic stress (He et al, 2007). A direct comparison of miR expression in CD34+ cells from LR and HR showed only 4 miR’s that are differentially expressed with significant fold changes; mir-656 (53x), mir-498 (32x), mir-181b (−17x) and mir-130a (−4x). Such differences where not observed in TNC from LR and HR samples. A 4-way intersect analysis on TNC’s from LR (n=47), del(5q) (n=5), HR (n=50) and −7 (n=8) cases identified 8 common miR’s; mir-34b, mir-139, mir-429, mir-519a, mir-548b, mir-561, mir-580 and mir-619. Comparison of the miR expression in TNC from AML samples against normal TNC identified 49 differentially expressed miR’s including let-7e, mir-181a, mir- 181b, mir-199a and mir-221 in accordance with previous published miR profiles in AML (Dixon-McIver et al, 2008). We also observed a 17 fold down regulation of mir-127 which is often silenced in cancer cells due to the methylation and acetylation status of the mir-127 promoter. The proto-oncogene BCL6 is a verified target of mir-127 (Saito et al, 2006). To our knowledge this is the first study in MDS that shows unique miR profiles in TNC for each subgroup when compared to normal TNC. Furthermore, miR profiles from CD34+ cells distinguish between the different MDS subtypes. In conclusion our analysis has shown that profiling miR’s in MDS results in unique profiles which may be used to discriminate between HR and LR MDS subgroups.
26
ZANARDI, RAFAEL PEREIRA, SILVIA BEATRIZ ALVES ROLIM, CLÁUDIO BIELENKI JÚNIOR, and CARLOS ALUISIO MESQUITA DE ALMEIDA. "Avaliação de Desempenho no Georreferenciamento de Imagens do Sensor HR CCD (High Resolution Charge-Coupled Device) do Satélite CBERS-1." Pesquisas em Geociências 32, no. 2 (December 31, 2005): 81. http://dx.doi.org/10.22456/1807-9806.19548.
Full textAbstract:
In this work it was analyzed the validation of CBERS-1 (China and Brazillian Earth Resourses Satellite) data related to qualitative and quantitative parameters that define the precision of its georeferencing. A topographical survey was carried out for the acquisition of ground control points spatially well distributed in the study area, employing differential GPS, aiming at the georeferencing of the image. Tests with different numbers of sampling points and several methods of Geometric Transformation and Resampling were made during the georeferencing. These results were statistically analyzed to determine the best method to georeference CBERS-1 images. It was verified that the first-degree polinomial transformation with nearest neighborhood resampling presented the best result, showing a precision of 18,52m.
27
Schwind, Sebastian, Madlen Jentzsch, Marius Bill, Karoline Schubert, Laura Schmalbrock, Heike Weidner, Laura Kloss, et al. "High Pri-Mir-181a-1 and Pri-Mir-181a-2 Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning." Blood 124, no. 21 (December 6, 2014): 732. http://dx.doi.org/10.1182/blood.v124.21.732.732.
Full textAbstract:
Abstract Introduction: Despite progress in understanding acute myeloid leukemia (AML) biology, most patients (pts) still have a poor prognosis. MicroRNAs (miR) have emerged as important players in AML biology. High expression of miR-181a has been associated with improved outcomes in AML pts. Mature miR-181a originates from two precursor molecules pri-miR-181a-1 & pri-miR-181a-2 which have been associated with distinct biological features & are derived from chromosome 1q32.1 & 9q33.3, respectively. Allogeneic stem cell transplantation (HCT) offers a potential curative treatment option for AML pts. With the introduction of reduced intensity conditioning (RIC) regimens, this procedure also became available for older or comorbid individuals. Here, we measured pri-miR-181a-1 & pri-miR-181a-2 and analyzed their impact on survival in RIC-HCT treated AML pts. Patients and Methods: 139 AML pts (median age 64 years [y], range 22-75y) who received RIC-HCT between 2000 and 2012 with pretreatment material available were included in our analysis. The conditioning regimens were based on Fludarabine 30mg/m2 on day -4 till -1 followed by 2 Gy total body irradiation. Disease status at RIC-HCT was first (n=79, 57%) or second complete remission (CR; n=23, 16%) or more advanced disease (n=37, 27%). Donors were human leukocyte antigen (HLA) matched related (n=22, 16%) or HLA matched (n=83, 60%) or mismatched (n=34, 24%) unrelated. The mutation status of the NPM1 & CEBPA genes & the FLT3-ITD status were assessed at diagnosis. Pts were grouped according to the European LeukemiaNet (ELN) classification in favorable (26%), intermediate-I (26%), intermediate-II (21%) or adverse (27%). Pri-miR-181a-1 & pri-miR-181a-2 expressions were measured by RT-PCR, normalized to 18S & the median normalized gene expression was used to define high & low expressers. Median follow up was 4.3y for pts alive. Results: The expression of both precursor molecules correlated well (Pearson Correlation 0.78), but 23% had a discordant expression status. At diagnosis pts with high pri-miR-181a-1 expression were younger at time of RIC-HCT (P=.01), had higher % peripheral blood (P=.05) & bone marrow (P=.04) blasts & by trend fewer NPM1 mutations (P=.054). Pts with high pri-miR-181a-2 expression had higher white blood count (WBC, P=.04). Combining the expression status information for both precursors, pts with high pri-miR-181a-1 and/or high pri-miR-181a-2 expression were younger at time of RIC-HCT (P=.04).Pts with high pri-miR-181a-1 and/or high pri-miR-181a-2 expression had longer overall survival (OS; P=.004, Figure 1) & event-free survival (EFS; P=.002). Interestingly a strong impact on outcome was observed in the ELN favorable group (OS: P=.001 & EFS: P=.008, Figure 1) and in the ELN intermediate II group (OS: P<.001 & EFS: P<.001, Figure 1), while no significant impact of high pri-miR-181a-1 and/or high pri-miR-181a-2 expression on outcome was observed in the intermediate I & adverse ELN groups.In multivariate analyses pri-miR-181a-1 and/or high pri-miR-181a-2 expression status remained a strong prognostic factor for OS (hazard ratio [HR] 0.53; 95% confidence interval [CI] 0.36-0.79; P=.002) and EFS (HR 0.52 CI 0.36-0.75; P<.001) in the entire group of pts. Conclusion: In conclusion, pri-miR-181a-1 & pri-miR-181a-2 expression correlated well, but were not fully concordant & associated with distinct clinical characteristics. The expression status of pri-miR-181a-1 & pri-miR-181a-2 at diagnosis is a strong independent prognostic factor for AML pts undergoing RIC-HCT. The prognostic impact was strongest in the ELN favorable and intermediate II groups. Pri-miR-181a-1 & pri-miR-181a-2 expression levels may contribute to improved risk stratification for AML pts undergoing RIC-HCT, refining the ELN favorable and intermediate II group. Furthermore, pretherapeutic miR elevation either pharmacologically or by miR-replacement therapies may improve outcomes in AML pts undergoing RIC-HCT. Figure 1 Figure 1. Disclosures Lange: Novartis: Consultancy, Honoraria, Research Funding.
28
Pesha, Anastasia V. "Assessment of the importance and self-esteem of digital competencies development for future HR managers." Herald of Omsk University. Series: Economics 18, no. 3 (December 7, 2020): 98–108. http://dx.doi.org/10.24147/1812-3988.2020.18(3).98-108.
Full textAbstract:
The importance of development, evaluation and formation of the digital competencies of a modern specialist is growing every year, and the scientists' interest all over the world in this area is the proof of it. In this article, we present a theoretical overview of a global research on the digital competencies emphasising on their development in the higher education. In the empirical part of the article, the aurthors show the results of a students' online survey of 8 Russian universities ( n = 231, the bachelor's degree program "Human Resources Management") which is pointed out the importance of the digital competencies in the labor market. The authors stresse that there are significant statistically differences between the two distributions of answers to questions about the importance and self-assessment of the digital competencies by students in all competencies, except "information management". Analyses showed significant statistical differences in the two analyzed distributions-answers to questions about the importance and opportunities for the development of digital competencies at the University. This allowed the authors to overturn the hypothesis that the level of opportunities for the development of the digital competencies at the University is responded to the assessment of their importance in the labor market according to the opinion of the surveyed students. It is concluded that students who studied "Human resourses management" are aware of the importance of developing the digital competencies for a modern HR manager in the labor market. The authors stress the necessity to increase the focus of the professional education on expanding opportunities and modifying curricula of the disciplines with the inclusion of the digital tools. This are supposed to help the future gradutes successfully entering the digital reality of the labor market.
29
FENG, XUEBING, YAOHONG ZOU, WENYOU PAN, XIANGDANG WANG, MIN WU, MIAOJIA ZHANG, JUAN TAO, et al. "Prognostic Indicators of Hospitalized Patients with Systemic Lupus Erythematosus: A Large Retrospective Multicenter Study in China." Journal of Rheumatology 38, no. 7 (April 1, 2011): 1289–95. http://dx.doi.org/10.3899/jrheum.101088.
Full textAbstract:
Objective.To investigate the mortality of hospitalized patients with systemic lupus erythematosus (SLE) and determine the influential factors associated with poor prognosis.Methods.Medical records of 1956 SLE inpatients from 15 hospitals during the period January 1, 1999, to December 31, 2009, were reviewed. All patients were followed up in January 2010. Potential factors associated with mortality were analyzed, comparing patients who were living with those who were deceased. The independency of those factors significantly related to death was determined by Cox regression analysis.Results.Male to female ratio was 1:15 in this cohort; median age at disease onset was 30 years. Hematologic (70.0%), mucocutaneous (68.2%), musculoskeletal (57.9%), and renal (48.7%) involvements were most often seen in these patients at time of admission. The overall mortality was 8.5% (n = 166), with infection (25.9%), renal failure (19.3%), and neuropsychiatric lupus (18.7%) the leading 3 causes of death. Independent predictors for mortality in this cohort of SLE patients were neuropsychiatric involvement [hazard ratio (HR) 2.19], anemia (HR 1.69), SLEDAI score > 8 at discharge (HR 1.64), increased serum creatinine (HR 1.57), low serum albumin (HR 1.56), cardiopulmonary involvement (HR 1.55), and patient untreated before admission (HR 1.48), whereas the use of antimalarial drugs (HR 0.62) and positive anti-Sm antibody (HR 0.60) were shown to be protective factors.Conclusion.SLE patients with delayed treatment and refractory disease have poorer prognosis. A high incidence of death would be expected if they have neuropsychiatric involvement, anemia, azotemia, or cardiopulmonary involvement. Combination therapy with antimalarial drugs may provide some benefit to patients with SLE.
30
Khouri, Issa F., Simone Anfossi, Rima M. Saliba, Lisa S. St. John, Jeffrey J. Molldrem, and James M. Reuben. "Serum miRNA Expression and Allogeneic Stem Cell Transplantation in Patients with B Chronic Lymphocytic Leukemia (CLL)." Blood 124, no. 21 (December 6, 2014): 5791. http://dx.doi.org/10.1182/blood.v124.21.5791.5791.
Full textAbstract:
Abstract Background: Noncoding RNAs play an important role in the pathogenesis of CLL. Recent publications suggested that higher miR-155 plasma levels (above 56th percentile) were associated with a significantly lower survival rate (P= 0.0122) in CLL patients treated with conventional treatments (Ferrajoli et al. Blood 2013;122:1891). Other studies revealed that expression of miR-29b or miR-181b significantly inhibits T cell leukemia/lymphoma 1(Tcl1) oncogene (Pekarsky et al. Cancer Res 2006;66:11590) whereas high Tcl1 expression correlates with aggressive CLL phenotype showing unmutated immunoglobulin variable region genes and ZAP70 positivity. The impact of these miR expressions in CLL patients undertaking allogeneic stem cell transplantation (alloSCT) is unknown. Methods and Patients: We identified 41 patients with relapsed/refractory CLL who had received a non-myeloablative alloSCT at our center and in whom pre-transplant serum samples collected before initiating the patients’ allogeneic conditioning were available. We measured the serum expression of miR-155 as well as miR-15a/16-1 cluster, miR-29b and miR-181b. Total RNA was isolated from 100 µL of serum using the Total RNA Purification Kit. Serum miRNA levels were measured by qRT-PCR (TaqMan MicroRNA assays). The relative serum levels of miR-155, miR -15, miR-29b, miR-181b, and miR-16-1 were calculated using the equation 2−ΔCt, where ΔCt = mean CtmiRNA – mean Ctcel-miR-39, and Ct = threshold cycle. Twenty fmol of synthetic C. elegans miRNA (cel-miR-39) was spiked into each serum samples to normalize the experimental qRT-PCR data (cel-miR-39 Ct mean ± SD = 17.777± 0.628). Forty one patients were initially evaluated. Thirteen of these 41 patients were later excluded as they received alemtuzumab for graft-versus-host disease (GVHD) prophylaxis. Therefore, our analysis was limited to 28 patients who received their alloSCT between 2000-2010. Median age (range) was 59 (45-70) years. Median number of prior therapies was 3 (range, 2-8). Eleven (39%) had a beta-2 microglobulin level of >3 mg/L. Ten of 12 (83%) patients with data that could be evaluated had unmutated immunoglobulin variable-region heavy-chain gene, and 4/19 (21%) had 17p13.1 deletion. 46% of patients had refractory disease at transplantation. The proportion of patients who received a matched related and a matched unrelated donor was 68% and 32%, respectively. All patients received non-myeloablative conditioning with fludarabine, cyclophosphamide, and rituximab as previously published (Khouri et al. Cancer 2011;117:4679). GVHD prophylaxis consisted of tacrolimus and methotrexate. Results: Median (range) follow-up months was 68 (43-141). OS from the time of alloSCT was studied according to the relative expressions of miR under investigation (low, below median; high, above median). The 5-year OS rates of patients with low and high mir-155 were 63% and 50%, respectively (HR=1.6, P=0.4; Figure). No statistically significant differences were found in the other miRs studied. The 5-year OS was 57% for both the low and high miR-15a expression. The 5-year OS in low and high miR-29b and miR-181b were 52% and 61% (HR=0.8; P=0.7), and 60% and 53% (HR=1.1, P=0.9), respectively. The 5-year OS in low and high miR-16 were 43% and 71% (HR=0.4, P=0.2). Conclusions: Our preliminary results suggest that serum levels of miR-155, miR -15, miR-29b, miR-181b, and miR-16 are not a statistically significant prognostic biomarker for survival in relapsed/refractory CLL undertaking alloSCT. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
31
Lee, Jong-Chan, Junhyeon Cho, Yohan Park, Young Sun Ro, and Hyejin Choi. "Venous thromboembolism in patients with pancreatic cancer: Incidence and effect on survival in east Asian ethnic groups." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 151. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.151.
Full textAbstract:
151 Background: Pancreatic cancer is known to be most frequently associated with venous thromboembolism (VTE), with the incidence of 10~20% in Western countries. As for the East Asian ethnic groups, just one small retrospective study showed lower incidence (5.3%) than other ethnic groups. However, there have been no large retrospective cohort studies of VTE in pancreatic cancer of East Asian ethnic group. Methods: We retrospectively reviewed the medical records of patients diagnosed with pancreatic adenocarcinoma in 2005~2010 at Severance Hospital, Seoul, Korea. Principal outcomes were incident VTE events and mortality. Cox proportional hazards models were used to analyze associations between specific risk factors and principal outcomes. Results: We investigated 1334 patients with pancreatic adenocarcinoma and 218 (16.3%) patients were excluded due to incomplete medical records and loss to follow-up. Among 1116 eligible patients, the overall and 1-year cumulative VTE incidence were 13.9% and 11.2% respectively. The incidence rate during the half year, 1-year and 2-years were 23.4, 17.7, 15.6 events per 100 person-years, respectively. Among total of 155 VTE patients, abdominal VTE was 52.9%, deep vein thrombosis was 21.3%, pulmonary thromboembolism was 19.4%, and head and neck VTE was 18.7%. In multivariable analyses, significant predictors of developing VTE included advanced metastatic stage (HR=2.08, 95% CI 1.37 to 3.17) and treatment of chemotherapy or radiotherapy, including CCRT (HR=1.52, 95% CI 16 to 1.99). VTE was a significant risk factor of 1-year and overall mortality (HR=1.44, 95% CI 1.15 to 1.79 and HR=1.45, 95% CI 1.21 to 1.73). Among 155 VTE patients, head and neck (H&N) VTE revealed highest risk of overall mortality (HR=2.05, 95% CI 1.27 to 3.33, versus non-H&N VTE). Conclusions: Approximately 13.9% of pancreatic adenocarcinoma patients developed VTE in East Asian ethnic group and this incidence was not significantly different from other ethnic groups. Advanced metastatic stage was the strongest predictor of VTE which would be a significant risk factor of 1-year mortality. Among VTE patients, head and neck VTE was 18.7% and showed the highest risk of overall death.
32
Ludwig, Heinz, Georg Slavka, Wolfgang Hübl, Hugh Carr-Smith, Dejan Milosavljevic, Richard Hughes, Niklas Zojer, and Stephen Harding. "Usage of HLC-Ratio, FLC-Ratio, Ife, PBMC Infiltration and Isotype Suppression At Best Response Reveals Isotype Suppression As Most Powerful Parameter for Identification of Multiple Myeloma Patients with Long Survival." Blood 120, no. 21 (November 16, 2012): 1817. http://dx.doi.org/10.1182/blood.v120.21.1817.1817.
Full textAbstract:
Abstract Abstract 1817 Introduction: Identifying patients with optimal response and long survival is important for clinical guidance because patients with these features are likely not to need further therapy. The techniques applied for classifying these patients should be readily available, standardized, and not liable to subjective interpretation. Here we compare the clinical usability of Hevylite™ (HLC) assay, FLC assay, IFE (immunofixation electropheresis), PMPC (bone marrow plasma cell) infiltration and isotype suppression for identifying patients at their best response with long term survival. Methods and Patients: 65 multiple myeloma patients (median age at maximum response 64, range 33–85; 42 IgG, 23 IgA) were enrolled following the minimum assignment of very good partial response using international myeloma working group guidelines. Patients had been enrolled into various clinical trials and been treated with different induction protocols (VAMP, VMCP+IFNa2b, Thal-Dex, MP, VMP). Median follow was 4.5 years, range 0.5–12 years. Heavy/light chain analysis was retrospectively performed for the monoclonal plasma cell immunoglobulin and its isotype matched pair (42 IgGκ / IgGλ and 23 IgAκ / IgAλ) using commercially available immunoassays (Hevylite™, The Binding Site, Birmingham, UK). Isotype matched immunoparesis was recorded if the patients immunoglobulin concentration was 33% below the bottom of the normal range (IgGk, IgGl, IgAk, IgAl), similarly immunoparesis was assessed if the patients total immunoglobulin levels were 33% below the normal range (IgG, IgA, IgM). Results were compared to bone marrow biopsy, serum free light chain (Freelite™, The Binding Site, Birmingham, UK) and standard immunoglobulin assays. Overall survival was estimated by the product limiting method of Kaplan Meier and survival compared using the log rank test, proportional hazards were assessed using the Cox proportional hazard model. Results: Comparison of patients at maximum response with and without IF-positivity, abnormal HLC ratios, abnormal FLC ratios or BMPC infiltration >5% did not reveal significantly different survival rates. Only patients with an abnormal HLC ratio showed a tendency for shorter survival (table 1). When all markers were combined a difference in the 5 year survival rate was noted (50% as compared to 100%), but due to the limited power, the statistical analysis revealed a tendency for reduced survival only. Discrimination of patients according to HLC pair suppression produced a highly significant difference in overall survival with a 5 year survival rate of 43% compared to 70% (figure 1). Median overall survival was 4.8 years vs. 8.5 years (HR, 2.5 CI: 1.1–5.54,p <0.02). In contrast, suppression of the non-involved isotype immunoglobulin (i.e. IgG concentrations in an IgA MM patient) was not found to be associated reduced overall survival (IgG or IgA, p=0.75, IgM, p=0.9) Discussion: These findings show the importance of immunoparesis at time of maximum response. This phenomenon is specific to the non-involved isotype matched immunoglobulin suggesting a preferential isotype specific inhibition mechanism not previously identified. Interestingly, among the other parameters only abnormal heavy light chain ratio showed a tendency for shorter survival. However, when all of the factors were considered together a small population (4/61, 7%) was identified as having an exceptionally long remission (OS, median: 5.9 years (2.0 – 10.2) Conclusion: The non-involved isotype matched pair suppression has previously been shown to be a prognostic factor in MGUS transformation and in predicting progression free survival in MM patients. Here for the first time we identify this marker as being the most important marker in predicting outcome at maximum response. Disclosures: Carr-Smith: Binding Site: Employment. Hughes:Binding Site: Employment. Harding:Binding Site: Employment.
33
Dhakal, Ajay, Roby Antony Thomas, Ellis G. Levine, Adam Brufsky, Kazuaki Takabe, Matthew G. Hanna, Kristopher Attwood, et al. "Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib." Breast Cancer: Basic and Clinical Research 14 (January 2020): 117822342094486. http://dx.doi.org/10.1177/1178223420944864.
Full textAbstract:
Background: Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in the management of hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), the optimal sequence of therapy is unclear. There are no clinical data on efficacy of everolimus in HR+ HER2-MBC after cancer progresses on CDK4/6 inhibitors. Objective: The objective of this study is to find the efficacy of everolimus in HR+ HER2-MBC after they progress on a CDK4/6 inhibitor palbociclib. Methods: This is a retrospective, 2-institute review of HR+ HER2-MBC from Jan 2015 to March 2018 treated with everolimus after progression on palbociclib. Primary end point was median progression-free survival (PFS), secondary end points objective response rate (ORR), clinical benefit ratio (CBR), and overall survival (OS). Results: Out of 41 women with median age 61 years (33, 87) enrolled, 66% had received adjuvant systemic therapy, 61% had visceral disease, and 95% had prior nonsteroidal aromatase inhibitors. About 83% women had 3 or more chemotherapy or hormonal therapies prior to everolimus. Kaplan-Meier estimates showed a median PFS of 4.2 months (95% confidence interval [CI]: 3.2-6.2). The median OS was 18.7 months (95% CI 9.5 to not reached). Objective response rate and CBR were both 17.1%. Conclusion: Everolimus was associated with modest PFS and ORR in HR+ HER2-MBCs postprogression on palbociclib.
34
Sumption, M. D., L. R. Motowidlo, G. Ozeryansky, G. Galinski, and E. W. Collings. "A comparison of ac loss, magnetization, Hr and U0 for Bi:2212 wires, crystals and melt grown samples." Applied Superconductivity 3, no. 7-10 (July 1995): 521–33. http://dx.doi.org/10.1016/0964-1807(95)00080-1.
Full text
35
Baiandina, Iu S., and A. N. Khanaychenko. "Water turbulence effect on egg survival and characteristics of hatched larvae of the Black Sea turbot Scophthalmus maeoticus (Pallas, 1814)." Marine Biological Journal 3, no. 4 (December 28, 2018): 101–5. http://dx.doi.org/10.21072/mbj.2018.03.4.11.
Full textAbstract:
The impact of different level of turbulence on developing eggs and prelarvae of the Black Sea turbot Scophthalmus maeoticus obtained from the pair of wild spawners at the end of natural spawning season has been studied. The incubation was carried out at three different levels of turbulence generated by diffused aeration: without aeration (calm water), low aeration (34 ml per minute) and high aeration (75 ml per minute). In calm water hatching rate (HR) of turbot eggs was 20 % and the hatched prelarvae had the longest standard length (SL = 3.13 mm) and the biggest volume of the yolk sac (VYS = 0.37 mm³) as compared to those of low aeration (HR = 18 %; SL = 3.10 mm; VYS = 0.32 mm³) and high aeration conditions (HR = 14 %; SL = 3.10 mm; VYS = 0.29 mm³). One day after hatching the percentage of survived prelarvae from the number of hatched was the highest – 86 % at high aeration, compared with that of low aeration (72 %) and calm water (61 %). Application of turbulence leads to elimination of “poor” quality eggs during incubation, presumably enables hatching of more viable larvae and can reduce mortality of more advanced larvae.
36
Mohee, Kevin, Amalan Karthigeyan, Stephen B. Wheatcroft, and Katarzyna Kucharska. "Cardiac abnormalities in anorexia nervosa inpatients – a retrospective study." Polish Journal of Public Health 125, no. 3 (September 1, 2015): 125–28. http://dx.doi.org/10.1515/pjph-2015-0038.
Full textAbstract:
Abstract Introduction. Anorexia nervosa (AN) is a life-threatening condition, with significant risk of death due to cardiac abnormalities. Aim. The aim of this study was to investigate for QTc interval or heart rate (HR) abnormalities in AN patients and any correlation between BMI, HR and QTc interval at baseline and at completion of treatment. Material and methods. 30 patients (29 females, 1 male) aged 16 to 45 years with a diagnosis of AN were retrospectively analyzed from January 2012 to September 2014. An ECG, biochemical tests, BMI and clinical assessment were performed on admission. ECG and BMI were also repeated at discharge. Results. A paired t-test was used to compare two sets of scores that come from the same participants on both admission and discharge. The mean baseline BMI was 14.8 +/− 4 kg/m2, baseline HR was 53.4 +/− 16 bpm and QTc interval 416 +/− 40 ms. At discharge, mean BMI was 18.7 +/− 2 kg/m2, HR was 73 +/− 11 bpm and QTc interval 402 +/− 34. The mean QTc interval was decreased by 14 ms and the HR increased by 19 beats/min. A Wilcoxon test showed that the treatment course did not elicit a statistically significant change in HR score in individuals with AN (Z=−4, p=0.000). Pearson correlations showed that patients with a higher magnesium had lower heart rate on admission (r=−0.61; p=0.002). Conclusion. Further exploration is needed in a larger population to investigate for etiology and medical management of cardiac abnormalities in AN.
37
Kondrotienė, Aistė, Albertas Daukša, Daina Pamedytytė, Mintautė Kazokaitė, Aurelija Žvirblienė, Dalia Daukšienė, Vaida Simanavičienė, et al. "Papillary Thyroid Carcinoma Tissue miR-146b, -21, -221, -222, -181b Expression in Relation with Clinicopathological Features." Diagnostics 11, no. 3 (March 2, 2021): 418. http://dx.doi.org/10.3390/diagnostics11030418.
Full textAbstract:
We analyzed miR-146b, miR-21, miR-221, miR-21, and miR-181b in formalin fixed paraffin-embedded papillary thyroid carcinoma (PTC) tissue samples of 312 individuals and evaluated their expression relationship with clinicopathological parameters. A higher expression of miR-21 was related to unifocal lesions (p < 0.011) and autoimmune thyroiditis (0.007). miR-221, miR-222 expression was higher in the PTC tissue samples with extrathyroidal extension (p = 0.049, 0.003, respectively). In a group of PTC patients with pT1a and pT1b sized tumors, the expression of miR-146b, miR-21, miR-221, and miR-222 in PTC tissue samples was lower than in patients with pT2, pT3, and pT4 (p = 0.032; 0.0044; 0.003; 0.001; 0.001, respectively). Patients with lymph node metastases had higher expression of miR-21, -221, -222, and -181b (p < 0.05). A high expression of miR-146b, miR-21, miR-221 panel was associated with decreased overall survival (OS) (Log rank p = 0.019). Univariate analysis revealed that presence of metastatic lymph nodes and high expression of miR-146b, miR-21, and miR-221 panels were associated with increased hazard of shorter OS. After multivariate analysis, only sex (male) and age (≥55 years) emerged as independent prognostic factors associated with shorter OS (HR 0.28 (95% CI 0.09–0.86) and HR 0.05 (95% CI 0.01–0.22), respectively). In conclusion, 5 analyzed miRs expression have significant relations to clinicopathologic parameters so further investigations of these molecules are expedient while searching for prognostic PTC biomarkers.
38
Parikh, Ravi, Angel Cronin, David E. Kozono, Geoffrey R. Oxnard, Raymond H. Mak, David Michael Jackman, Peter C. Lo, Elizabeth H. Baldini, Bruce E. Johnson, and Aileen B. Chen. "Factors associated with survival in non-small cell lung cancer (NSCLC) patients with a solitary metastasis." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e19121-e19121. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19121.
Full textAbstract:
e19121 Background: Although palliative chemotherapy is the standard of care for metastatic NSCLC, somepatients with oligometastatic disease may benefit from aggressive local therapy. We investigated factors associated with greater survival among patients diagnosed with a solitary metastatic lesion. Methods: We identified patients diagnosed with stage IV NSCLC who presented with a solitary metastatic lesion based on PET and MRI and who were prospectively consented and enrolled in our institutional database from 2002-2011. Univariable and multivariable Cox proportional hazards models were used to analyze factors associated with overall survival among this cohort. Results: We identified 110 patients (10.7% of stage IV patients) meeting our inclusion criteria. Median age at diagnosis was 61 years, 50% of patients were female, 66% had adenocarcinoma histology, and 35% had N0-1 disease. Median survival from diagnosis was 18.7 months, with a median followup of 31.5 months. On univariable analysis, greater overall survival was associated with ECOG performance status 0-1 vs 2+ (median 21.5 months vs 12.6 months, HR 0.32, p<0.01); weight loss <2 vs >2 kg (22.4 vs 13.8, HR 0.56, p=0.03); and N stage 0-1 vs 2-3 (32.0 vs 17.6, HR 0.52, p=0.02). Adenocarcinoma vs non-adenocarcinoma histology (22.9 vs 13.8, HR 0.65, p=0.07) was borderline significant. Age, gender, race, current smoking, size of primary tumor, and metastatic organ were not significantly associated with survival. On multivariable analysis, adenocarcinoma histology (HR= 0.58, p=0.06); N stage 0-1 (HR= 0.43, p=0.01); and weight loss <2 kg (HR 0.53, p=0.03) were associated with greater overall survival. Conclusions: Select patient and tumor characteristics may predict for improved survival among patients with oligometastatic NSCLC. Future studies will evaluate the impact of aggressive local therapy in these patients.
39
Magro, Bianca, Valentina Zuccaro, Luca Novelli, Lorenzo Zileri, Ciro Celsa, Federico Raimondi, Mauro Gori, et al. "Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use." PLOS ONE 16, no. 1 (January 14, 2021): e0245281. http://dx.doi.org/10.1371/journal.pone.0245281.
Full textAbstract:
Backgrounds Validated tools for predicting individual in-hospital mortality of COVID-19 are lacking. We aimed to develop and to validate a simple clinical prediction rule for early identification of in-hospital mortality of patients with COVID-19. Methods and findings We enrolled 2191 consecutive hospitalized patients with COVID-19 from three Italian dedicated units (derivation cohort: 1810 consecutive patients from Bergamo and Pavia units; validation cohort: 381 consecutive patients from Rome unit). The outcome was in-hospital mortality. Fine and Gray competing risks multivariate model (with discharge as a competing event) was used to develop a prediction rule for in-hospital mortality. Discrimination and calibration were assessed by the area under the receiver operating characteristic curve (AUC) and by Brier score in both the derivation and validation cohorts. Seven variables were independent risk factors for in-hospital mortality: age (Hazard Ratio [HR] 1.08, 95% Confidence Interval [CI] 1.07–1.09), male sex (HR 1.62, 95%CI 1.30–2.00), duration of symptoms before hospital admission <10 days (HR 1.72, 95%CI 1.39–2.12), diabetes (HR 1.21, 95%CI 1.02–1.45), coronary heart disease (HR 1.40 95% CI 1.09–1.80), chronic liver disease (HR 1.78, 95%CI 1.16–2.72), and lactate dehydrogenase levels at admission (HR 1.0003, 95%CI 1.0002–1.0005). The AUC was 0.822 (95%CI 0.722–0.922) in the derivation cohort and 0.820 (95%CI 0.724–0.920) in the validation cohort with good calibration. The prediction rule is freely available as a web-app (COVID-CALC: https://sites.google.com/community.unipa.it/covid-19riskpredictions/c19-rp). Conclusions A validated simple clinical prediction rule can promptly and accurately assess the risk for in-hospital mortality, improving triage and the management of patients with COVID-19.
40
Migliore, Enrica, Amelia Brunani, Giovannino Ciccone, Eva Pagano, Simone Arolfo, Tiziana Rosso, Marianna Pellegrini, et al. "Effect of Bariatric Surgery on Survival and Hospitalizations in Patients with Severe Obesity. A Retrospective Cohort Study." Nutrients 13, no. 9 (September 9, 2021): 3150. http://dx.doi.org/10.3390/nu13093150.
Full textAbstract:
Bariatric surgery (BS) confers a survival benefit in specific subsets of patients with severe obesity; otherwise, effects on hospital admissions are still uncertain. We assessed the long-term effect on mortality and on hospitalization of BS in patients with severe obesity. This was a retrospective cohort study, including all patients residing in Piedmont (age 18–60 years, BMI ≥ 40 kg/m2) admitted during 2002–2018 to the Istituto Auxologico Italiano. Adjusted hazard ratios (HR) for BS were estimated for mortality and hospitalization, considering surgery as a time-varying variable. Out of 2285 patients, 331 (14.5%) underwent BS; 64.4% received sleeve gastrectomy (SG), 18.7% Roux-en-Y gastric bypass (RYGB), and 16.9% adjustable gastric banding (AGB). After 10-year follow-up, 10 (3%) and 233 (12%) patients from BS and non-BS groups died, respectively (HR = 0.52; 95% CI 0.27–0.98, by a multivariable Cox proportional-hazards regression model). In patients undergoing SG or RYGB, the hospitalization probability decreased significantly in the after-BS group (HR = 0.77; 0.68–0.88 and HR = 0.78; 0.63–0.98, respectively) compared to non-BS group. When comparing hospitalization risk in the BS group only, a marked reduction after surgery was found for all BS types. In conclusion, BS significantly reduced the risk of all-cause mortality and hospitalization after 10-year follow-up.
41
Kitagawa, D. "The alternation of estrogen receptor (ER) and progesterone receptor (PgR) expression in primary breast cancer patients treated with neoadjuvant chemotherapy (NAC)." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 21165. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.21165.
Full textAbstract:
21165 Background: Currently, neoadjuvant chemotherapy (NAC) for the operable primary breast cancer has become standard treatment strategy. Primary treatment could affect the status of Estrogen receptor (ER) and Progesterone receptor (PgR) expressions in the tumor, and might have impact on the choice of adjuvant hormone therapy. Methods: We evaluated consecutive 165 primary breast cancer cases those treated with 4 cycles of FEC (500–100–500 mg/m2, q3wks) followed by 4 cycles docetaxel (75 mg/m2, q3wks) as their neoadjuvant treatment in our institution from January 2000 to February 2006. Except for the bilateral breast cancer cases and patients achieved pCR, 107 pairs of core needle biopsy before treatment and tumor block after surgery were evaluated by immunohistochemistry (IHC) for receptor status and analyzed by Allred scoring. Score 4 or more was designated as positive. Results: Median age of patients was 51 (23–71) years old. Hormone receptor (HR) phenotypes before treatment were following; ER+/PgR+:62(57.9%), +/ -:23(21.5%), -/ +:2(1.9%), -/ -:20(18.7%). As the HR status, 94.4 % of patients did not show any alternation for their HR evaluation. Only 4.7% of patients experienced changes from HR+ to HR-, and HR- to HR+ were extremely rare (0.9%). Although ER positivity was not changed in most of cases (95.1%), conversion from PgR + to - were observed in 35.5% of ER+/PgR+ cases. Particularly, the rate of negative conversion of PgR were found more frequently in patients with age under 50 (51.7% in <50y.o. vs. 22.6% in =50 y.o., p=0.03). Whereas, in older patients, negative conversion of PgR correlated to favorable pathological response. Conclusions: In most of patients, neoadjuvant chemotherapy did not affect the evaluation of HR status. Alternation of PgR expression seems to reflect the chemotherapy induced amenorrhea in younger patients. In the older patients, negative conversion of PgR may have some impact on pathological response. No significant financial relationships to disclose.
42
Toraih, Eman A., Mohammad H. Hussein, Mourad Zerfaoui, Abdallah S. Attia, Assem Marzouk Ellythy, Arwa Mostafa, Emmanuelle M. L. Ruiz, et al. "Site-Specific Metastasis and Survival in Papillary Thyroid Cancer: The Importance of Brain and Multi-Organ Disease." Cancers 13, no. 7 (April 1, 2021): 1625. http://dx.doi.org/10.3390/cancers13071625.
Full textAbstract:
Introduction—heterogeneity in clinical outcomes and survival was observed in patients with papillary thyroid cancer (PTC) and distant metastases. Here, we investigated the effect of distant metastases sites on survival in PTC patients. Methods—patients with a diagnosis of PTC and known metastases were identified using the Surveillance, Epidemiology, and End Results database (1975–2016). Univariate and multivariate Cox regression analyses were performed to analyze the effect of distant metastases sites on thyroid cancer-specific survival (TCSS) and overall survival (OS). Results—from 89,694 PTC patients, 1819 (2%) developed distant metastasis at the initial diagnosis, of whom 26.3% presented with the multiple-organ disease. The most common metastatic sites were lung (53.4%), followed by bone (28.1%), liver (8.3%), and brain (4.7%). In metastatic patients, thyroid cancer-specific death accounted for 73.2%. Kaplan–Meier curves showed decreased OS in patients with metastases to the brain (median OS = 5 months) and liver (median OS = 6 months) compared to lung (median OS = 10 months) and bone (median OS = 23 months). Moreover, multiple organ metastasis had a higher mortality rate (67.4%) compared to single organ metastasis (51.2%, p < 0.001). Using multivariate analysis, risk factors that significantly influence TCSS and OS were male gender (HR = 1.86, 95% CI = 1.17–2.94, p < 0.001, and HR = 1.90, 95% CI = 1.40–2.57, p = 0.009), higher tumor grade (HR = 7.31, 95% CI = 2.13–25.0, p < 0.001 and HR = 4.76, 95% CI = 3.93–5.76, p < 0.001), multiple organ involvement (HR = 6.52, 95% CI = 1.50–28.39, p = 0.026 and HR = 5.08, 95% CI = 1.21–21.30, p = 0.013), and brain metastasis (HR = 1.82, 95% CI = 1.15–2.89, p < 0.001 and HR = 4.21, 95% CI = 2.20–8.07, p = 0.010). Conclusion—the pattern of distant metastatic organ involvement was associated with variability in OS in PTC. Multi-organ metastasis and brain involvement are associated with lower survival rates in PTC. Knowledge of the patterns of distant metastasis is crucial to personalize the treatment and follow-up strategies.
43
Noh, Hyeonseok, Jeongju Jang, Seungwon Kwon, Seung-Yeon Cho, Woo-Sang Jung, Sang-Kwan Moon, Jung-Mi Park, Chang-Nam Ko, Ho Kim, and Seong-Uk Park. "The Impact of Korean Medicine Treatment on the Incidence of Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea." Journal of Clinical Medicine 9, no. 8 (July 28, 2020): 2422. http://dx.doi.org/10.3390/jcm9082422.
Full textAbstract:
We aimed to investigate the association between Korean medicine (KM) treatment and the risk of Parkinson’s Disease (PD) in patients with inflammatory bowel disease (IBD) in South Korea. This study analyzed data from the National Health Insurance Service-Senior cohort in South Korea. The 1816 IBD patients enrolled in the analysis comprised 411 who received only conventional treatment (monotherapy group) and 1405 who received both conventional and KM treatments (integrative therapy group). The risk of PD in patients with IBD was significantly lower in the integrative therapy group than in the monotherapy group after adjusting for confounding variables (adjusted hazard ratio (HR), 0.56; 95% confidence interval (CI) = 0.34–0.92). In the mild Charlson Comorbidity Index (CCI) group, the risk of PD in patients with IBD in the integrative therapy group was 0.39 times lower (adjusted HR, 95% CI = 0.20–0.77) than that in the monotherapy group. However, there was no significant difference in the risk of PD in patients with IBD between the integrative therapy and monotherapy groups among individuals with severe CCI (adjusted HR, 0.90; 95% CI = 0.41−1.96). IBD patients are at a decreased risk of PD when they receive integrative therapy. KM treatment may prevent PD in IBD patients.
44
Ding-Wei, Ye, and Zhang Hai-Lang. "Potential synergistic effects of bisphosphonates with sorafenib on renal cell carcinoma with bone metastases." Journal of Clinical Oncology 33, no. 7_suppl (March 1, 2015): 496. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.496.
Full textAbstract:
496 Background: We evaluated the role of bisphosphonates in conjunction with sorafenib in improving progression-free survival (PFS) and overall survival (OS) in bone metastatic renal cell carcinoma (mRCC) patients. Methods: A total of 81 sorafenib-treated patients were retrospectively divided into 3 groups at our single study center: Group 1 (n=26, sorafenib single agent); Group 2 (n=26, sorafenib plus oral Bonefos); Group 3 (n=29, sorafenib plus intravenous zoledronic acid). Alkaline phosphatase (ALP) before and 12 weeks after treatment were evaluated as prognostic factor for PFS and OS. Results: The majority of the patients were males (67.9%) with mean age of 57.2 ± 11.2 years. Baseline demographic characteristics were similar across the 3 study groups, and the known prognostic factors were balanced across the cohort. There was no significant difference observed in the objective response between the 3 study groups (Group 1 vs. 2 vs. 3; p=0.659); partial remission (8% vs. 8% vs. 10%), stable disease (65% vs. 80% vs. 66%), progressive disease (27% vs. 12% vs. 24%). Median PFS was significantly higher in Group 2 vs 1 vs 2 (18.7 vs. 6.7 vs. 10.5 months; p=0.024). Median OS was 16.8, 22.1, and 20.7 months; p=0.052 in Group 1, 2 and 3, respectively. Multivariate analysis demonstrated that bisphosphonate use (hazard ratio [HR]=0.36, p=0.006), Memorial Sloan Kettering Cancer Center (MSKCC) score (HR=4.10, p<0.001), non-clear cell subtype (HR=1.26, p=0.039), and elevated ALP after 12 weeks’ treatment (HR=3.53, p<0.001) were associated with PFS. MSKCC score (HR=5.24, p<0.001), elevated ALP after 12 weeks’ treatment (HR=4.71, p<0.001), and metastatic organs (HR=1.93, p=0.008) were associated with OS. Bisphosphonates use was not an independent predictor of OS (HR=0.55, p=0.160). Conclusions: Bisphosphonates administered with sorafenib could synergistically improve PFS and OS in RCC with bone metastases, with the benefit of being more efficacious and safer than intravenous zoledronic acid. Elevated ALP following the treatment could be an independent predictor for both PFS and OS in bone mRCC.
45
Dorobantu, Dan M., Alireza S. Mahani, Mansour T. A. Sharabiani, Ragini Pandey, Gianni D. Angelini, Andrew J. Parry, Robert M. R. Tulloh, Robin P. Martin, and Serban C. Stoica. "Primary repair versus surgical and transcatheter palliation in infants with tetralogy of Fallot." Heart 104, no. 22 (May 2, 2018): 1864–70. http://dx.doi.org/10.1136/heartjnl-2018-312958.
Full textAbstract:
ObjectivesTreatment of infants with tetralogy of Fallot (ToF) has evolved in the last two decades with increasing use of primary surgical repair (PrR) and transcatheter right ventricular outflow tract palliation (RVOTd), and fewer systemic-to-pulmonary shunts (SPS). We aim to report contemporary results using these treatment options in a comparative study.MethodsThis a retrospective study using data from the UK National Congenital Heart Disease Audit. All infants (n=1662, median age 181 days) with ToF and no other complex defects undergoing repair or palliation between 2000 and 2013 were considered. Matching algorithms were used to minimise confounding due to lower age and weight in those palliated.ResultsPatients underwent PrR (n=1244), SPS (n=311) or RVOTd (n=107). Mortality at 12 years was higher when repair or palliation was performed before the age of 60 days rather than after, most significantly for primary repair (18.7% vs 2.2%, P<0.001), less so for RVOTd (10.8% vs 0%, P=0.06) or SPS (12.4% vs 8.3%, P=0.2). In the matched groups of patients, RVOTd was associated with more right ventricular outflow tract (RVOT) reinterventions (HR=2.3, P=0.05 vs PrR, HR=7.2, P=0.001 vs SPS) and fewer pulmonary valve replacements (PVR) (HR=0.3 vs PrR, P=0.05) at 12 years, with lower mortality after complete repair (HR=0.2 versus PrR, P=0.09).ConclusionsWe found that RVOTd was associated with more RVOT reinterventions, fewer PVR and fewer deaths when compared with PrR in comparable, young infants, especially so in those under 60 days at the time of the first procedure.
46
Black, Katherine E., Paula M. L. Skidmore, and Rachel C. Brown. "Energy Intakes of Ultraendurance Cyclists During Competition, an Observational Study." International Journal of Sport Nutrition and Exercise Metabolism 22, no. 1 (February 2012): 19–23. http://dx.doi.org/10.1123/ijsnem.22.1.19.
Full textAbstract:
Endurance events >10 hr are becoming increasingly popular but provide numerous physiological challenges, several of which can be attenuated with optimal nutritional intakes. Previous studies in ultraendurance races have reported large energy deficits during events. The authors therefore aimed to assess nutritional intakes in relation to performance among ultraendurance cyclists. This observational study included 18 cyclists in a 384-km cycle race. At race registration each cyclist’s support crew was provided with a food diary for their cyclist. On completion of the race, cyclists were asked to recall their race food and drink intakes. All food and fluids were analyzed using a computer software package. Mean (SD) time to complete the race was 16 hr 21 min (2 hr 2 min). Mean (SD) energy intake was 18.7 (8.6) MJ, compared with an estimated energy requirement for the race of 25.5 (7.4) MJ. There was a significant negative relationship between energy intake and time taken to complete the race (p = .023, r2 = −.283). Mean (SD) carbohydrate, fat, and protein intakes were 52 (27), 15.84 (56.43), and 2.94 (7.25) g/hr, respectively. Only carbohydrate (p = .015, r2 = −.563) and fat intake (p = .037, r2 = −.494) were associated with time taken to complete the race. This study demonstrates the difficulties in meeting the high energy demands of ultraendurance cycling. The relationship between energy intake and performance suggests that reducing the energy deficit may be advantageous. Given the high carbohydrate intakes of these athletes, increasing energy intake from fat should be investigated as a means of decreasing energy deficits.
47
Severin, Richard, Edward Wang, Adam Wielechowski, and Shane A. Phillips. "Outpatient Physical Therapist Attitudes Toward and Behaviors in Cardiovascular Disease Screening: A National Survey." Physical Therapy 99, no. 7 (March 18, 2019): 833–48. http://dx.doi.org/10.1093/ptj/pzz042.
Full textAbstract:
AbstractBackgroundScreening the cardiovascular system is an important and necessary component of the physical therapist examination to ensure patient safety, appropriate referral, and timely medical management of cardiovascular disease (CVD) and risk factors. The most basic screening includes a measurement of resting blood pressure (BP) and heart rate (HR). Previous work demonstrated that rates of BP and HR screening and perceptions toward screening by physical therapists are inadequate.ObjectiveThe purpose was to assess the current attitudes and behaviors of physical therapists in the United States regarding the screening of patients for CVD or risk factors in outpatient orthopedic practice.DesignThis was a cross-sectional, online survey study.MethodsData were collected from an anonymous adaptive online survey delivered via an email list.ResultsA total of 1812 surveys were included in this analysis. A majority of respondents (n = 931; 51.38%) reported that at least half of their current caseload included patients either with diagnosed CVD or at moderate or greater risk of a future occurrence. A total of 14.8% of respondents measured BP and HR on the initial examination for each new patient. The most commonly self-reported barriers to screening were lack of time (37.44%) and lack of perceived importance (35.62%). The most commonly self-reported facilitators of routine screening were perceived importance (79.48%) and clinic policy (38.43%). Clinicians who managed caseloads with the highest CVD risk were the most likely to screen.LimitationsAlthough the sampling population included was large and representative of the profession, only members of the American Physical Therapy Association Orthopaedic Section were included in this survey.ConclusionsDespite the high prevalence of patients either diagnosed with or at risk for CVD, few physical therapists consistently included BP and HR on the initial examination. The results of this survey suggest that efforts to improve understanding of the importance of screening and modifications of clinic policy could be effective strategies for improving rates of HR and BP screening.
48
Morishima, Satoko, Seishi Ogawa, Aiko Matsubara, Takakazu Kawase, Yasuhito Nannya, Koichi Kashiwase, Masahiro Satake, et al. "Impact of highly conserved HLA haplotype on acute graft-versus-host disease." Blood 115, no. 23 (June 10, 2010): 4664–70. http://dx.doi.org/10.1182/blood-2009-10-251157.
Full textAbstract:
Abstract Although the effects of human leukocyte antigen (HLA) locus matching on clinical outcome in unrelated hematopoietic stem cell transplantations have been characterized, the biologic implications of HLA haplotypes have not been defined. We demonstrated the genetic fixity of Japanese conserved extended haplotypes by multi–single nucleotide polymorphism analysis in 1810 Japanese donor-recipient pairs matching with HLA-A, -B, -C, -DRB1, and -DQB1 alleles. Three major Japanese conserved extended haplotypes (named HP-P1, HP-P2, and HP-P3) were essentially completely conserved at least in the 3.3-Mb HLA region from HLA-A to -DPB1, and extended far beyond HLA-A. The risk of acute graft-versus-host disease (GVHD) of these HLA haplotypes was assessed with multivariate Cox regression in 712 patients transplanted from HLA fully (HLA-A, B, C, DRB1, DQB1, and DPB1) matched unrelated donors. HP-P2 itself reduced the risk of grade 2 to 4 acute GVHD (hazard ratio [HR] = 0.63; P = .032 compared with HP-P2-negative), whereas HP-P3 tended to increase the risk (HR = 1.38; P = .07). Among 381 patients with HP-P1, HP-P1/P3 (HR = 3.35; P = .024) significantly increased the risk of acute GVHD compared with homozygous HP-P1. This study is the first to demonstrate that a genetic difference derived from HLA haplotype itself is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation.
49
Heianza, Yoriko, Tao Zhou, Dianjianyi Sun, Frank B. Hu, JoAnn E. Manson, and Lu Qi. "Genetic susceptibility, plant-based dietary patterns, and risk of cardiovascular disease." American Journal of Clinical Nutrition 112, no. 1 (May 13, 2020): 220–28. http://dx.doi.org/10.1093/ajcn/nqaa107.
Full textAbstract:
ABSTRACT Background Plant-based dietary patterns may be related to better cardiovascular profiles. Whether a healthy plant-based dietary index is predictive of future cardiovascular disease (CVD) across people with different genetic susceptibility remains uncertain. Objective We investigated associations of adherence to healthy plant-based diets with the incidence of CVD considering the genetic susceptibility. Methods This prospective cohort study included a total of 156,148 adults initially free of CVD and cancer. We calculated a healthful plant-based diet index (healthful-PDI) in which healthy plant foods received positive scores, and less healthy plant foods and animal foods received reverse scores. Genetic risk scores (GRSs) for myocardial infarction (MI) and stroke were calculated to assess interactions between healthful-PDI and GRSs. Results During 5 y of follow-up, we observed 1812 incident cases of CVD. Higher healthful-PDI was associated with a lower CVD risk [HR per 10-unit increment: 0.87 (95% CI: 0.81, 0.93) after adjusting for demographic, lifestyle, and other dietary factors (model 1); HR 0.90 (0.84, 0.97) after further adjusting for obesity and metabolic factors (model 2)]. The risk of CVD was gradually decreased in association with higher adherence to healthful-PDI, regardless of genetic susceptibility. The inverse associations of healthful-PDI with CVD were consistently observed in people with low GRS-MI [HR 0.85 (95% CI: 0.76, 0.94) in model 1; HR 0.88 (0.79, 0.97) in model 2] and those with high GRS-MI [HR 0.91 (0.82, 0.99) in model 1; HR 0.94 (0.86, 1.04) in model 2], without significant interactions (Pinteraction = 0.59 in model 1; Pinteraction = 0.66 in model 2). Similarly, higher healthful-PDI was related to a lower risk of CVD, regardless of low/high GRS-stroke. Conclusion Adherence to healthy plant-based diets may be associated with a decreased incidence of CVD in the entire population, suggesting that plant-based dietary patterns may modify the risk of CVD, regardless of genetic susceptibility.
50
Yamamoto, Masaaki, Takuya Kawabe, Yasunori Sato, Yoshinori Higuchi, Tadashi Nariai, Shinya Watanabe, and Hidetoshi Kasuya. "Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors." Journal of Neurosurgery 121, Suppl_2 (December 2014): 16–25. http://dx.doi.org/10.3171/2014.8.gks141421.
Full textAbstract:
ObjectAlthough stereotactic radiosurgery (SRS) alone is not a standard treatment for patients with 4–5 tumors or more, a recent trend has been for patients with 5 or more, or even 10 or more, tumors to undergo SRS alone. The aim of this study was to reappraise whether the treatment results for SRS alone for patients with 10 or more tumors differ from those for patients with 2–9 tumors.MethodsThis was an institutional review board–approved, retrospective cohort study that gathered data from the Katsuta Hospital Mito GammaHouse prospectively accumulated database. Data were collected for 2553 patients who consecutively had undergone Gamma Knife SRS alone, without whole-brain radiotherapy (WBRT), for newly diagnosed (mostly) or recurrent (uncommonly) brain metastases during 1998–2011. Of these 2553 patients, 739 (28.9%) with a single tumor were excluded, leaving 1814 with multiple metastases in the study. These 1814 patients were divided into 2 groups: those with 2–9 tumors (Group A, 1254 patients) and those with 10 or more tumors (Group B, 560 patients). Because of considerable bias in pre-SRS clinical factors between groups A and B, a case-matched study, which used the propensity score matching method, was conducted for clinical factors (i.e., age, sex, primary tumor state, extracerebral metastases, Karnofsky Performance Status, neurological symptoms, prior procedures [surgery and WBRT], volume of the largest tumor, and peripheral doses). Ultimately, 720 patients (360 in each group) were selected. The standard Kaplan-Meier method was used to determine post-SRS survival times and post-SRS neurological death–free survival times. Competing risk analysis was applied to estimate cumulative incidence for local recurrence, repeat SRS for new lesions, neurological deterioration, and SRS-induced complications.ResultsPost-SRS median survival times did not differ significantly between the 2 groups (6.8 months for Group A vs 6.0 months for Group B; hazard ratio [HR] 1.133, 95% CI 0.974–1.319, p = 0.10). Furthermore, rates of neurological death were very similar: 10.0% for group A and 9.4% for group B (p = 0.89); neurological death–free survival times did not differ significantly between the 2 groups (HR 1.073, 95% CI 0.649–1.771, p = 0.78). The cumulative incidence of local recurrence (HR 0.425, 95% CI 0.0.181–0.990, p = 0.04) and repeat SRS for new lesions (HR 0.732, 95% CI 0.554–0.870, p = 0.03) were significantly lower for Group B than for Group A patients. No significant differences between the groups were found for cumulative incidence for neurological deterioration (HR 0.994, 95% CI 0.607–1.469, p = 0.80) or SRS-related complications (HR 0.541, 95% CI 0.138–2.112, p = 0.38).ConclusionsPost-SRS treatment results (i.e., median survival time; neurological death–free survival times; and cumulative incidence for local recurrence, repeat SRS for new lesions, neurological deterioration, and SRS-related complications) were not inferior (neither less effective nor less safe) for patients in Group B than for those in Group A. We conclude that carefully selected patients with 10 or more tumors are not unfavorable candidates for SRS alone. A randomized controlled trial should be conducted to test this hypothesis.